N-<(1,1-dimethylethoxy)carbonyl>-3-<(3-methyl-4-nitrophenyl)methyl>-L-histidine methyl ester | 114787-83-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 组氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-<(1,1-dimethylethoxy)carbonyl>-3-<(3-methyl-4-nitrophenyl)methyl>-L-histidine methyl ester
• 英文别名: 3-(3-methyl-4-nitrophenyl)methyl-N-t-butoxycarbonyl-L-histidine methyl ester；N-[(1,1-dimethylethoxy)carbonyl]-3-[(3-methyl-4-nitrophenyl)methyl]-L-histidine methyl ester；methyl (2S)-3-[3-[(3-methyl-4-nitrophenyl)methyl]imidazol-4-yl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 114787-83-6
• 化学式: C₂₀H₂₆N₄O₆
• 分子量: 418.45
• InChiKey: GQACPDRFESBMPS-INIZCTEOSA-N

物化性质

• 熔点：
  92-104 °C (lit.)
• 闪点：
  >230 °F

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  1,3
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338

反应信息

• 作为反应物：
  描述：

  N-<(1,1-dimethylethoxy)carbonyl>-3-<(3-methyl-4-nitrophenyl)methyl>-L-histidine methyl ester 在 盐酸 、 sodium hydroxide 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 反应 77.5h， 生成 (S)-(-)-4,5,6,7-tetrahydro-1-[(4-methoxy-3-methylphenyl)methyl]-5-(phenylacetyl)-1H-imidazo-[4,5-c]pyridine-6-carboxylic acid
  参考文献：
  名称：

  Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype

  摘要：

  Structure-activity relationships are reported for a novel class of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid derivatives that displace I-125-labeled angiotensin II from a specific subset of angiotensin II (Ang II) binding sites in rat adrenal preparations. This binding site is not the Ang II receptor mediating vascular contraction or aldosterone release, but, rather, is one whose function has not yet been fully elucidated. It has been identified in a number of tissues and has a similar affinity for Ang II and its peptide analogues as does the vascular receptor. The non-peptide compounds reported here are uniquely specific in displacing Ang II at this binding site and are inactive in antagonizing Ang II at the vascular receptor or in pharmacological assays measuring vascular effects. PD 123,319 (79), one of the most potent compounds, has an IC50 of 34 nM. Certain of these compounds may have utility in the definition and study of Ang II receptor subtypes.

  DOI：

  10.1021/jm00115a014
• 作为产物：
  描述：

  3-甲基-4-硝基苄醇 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成 N-<(1,1-dimethylethoxy)carbonyl>-3-<(3-methyl-4-nitrophenyl)methyl>-L-histidine methyl ester
  参考文献：
  名称：

  Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype

  摘要：

  Structure-activity relationships are reported for a novel class of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid derivatives that displace I-125-labeled angiotensin II from a specific subset of angiotensin II (Ang II) binding sites in rat adrenal preparations. This binding site is not the Ang II receptor mediating vascular contraction or aldosterone release, but, rather, is one whose function has not yet been fully elucidated. It has been identified in a number of tissues and has a similar affinity for Ang II and its peptide analogues as does the vascular receptor. The non-peptide compounds reported here are uniquely specific in displacing Ang II at this binding site and are inactive in antagonizing Ang II at the vascular receptor or in pharmacological assays measuring vascular effects. PD 123,319 (79), one of the most potent compounds, has an IC50 of 34 nM. Certain of these compounds may have utility in the definition and study of Ang II receptor subtypes.

  DOI：

  10.1021/jm00115a014

文献信息

• 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid amide
  申请人：Kureha Kagaku Kogyo Kabushiki Kaisha

  公开号：US05401736A1

  公开（公告）日：1995-03-28

  Disclosed herein are 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid amide derivatives having a high antagonistic activity against angiotensin II and a high specificity to angiotensin II receptors, intermediates for preparing the derivatives, and antagonists against angiotensin II comprising the derivatives.

  本文揭示了具有高拮抗活性对抗血管紧张素II和对抗血管紧张素II受体具有高特异性的4,5,6,7-四氢-1H-咪唑[4,5-c]吡啶-6-羧酸酰胺衍生物，用于制备这些衍生物的中间体，以及包括这些衍生物的抗血管紧张素II拮抗剂。
• 2-Quinoxalinol Salen Compounds and Uses Thereof
  申请人：Gorden Anne E. V.

  公开号：US20090286968A1

  公开（公告）日：2009-11-19

  Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.

  本文披露了2-喹啉醇Salen化合物，特别是2-喹啉醇Salen席夫碱配体。披露的2-喹啉醇Salen化合物可用作与阳离子形成络合物的配体，进而形成的络合物可用作氧化反应的催化剂。披露的2-喹啉醇Salen化合物还可以与固体支撑物结合，并用于选择性固相萃取或阳离子检测方法。
• 4,5,6,7-Tetrahydro-1H-imidazo 4,5-c pyridine-6-carboxylic acid amide derivatives as angiotensine II antagonistes
  申请人：KUREHA KAGAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0589665A2

  公开（公告）日：1994-03-30

  A compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein R¹ represents    hydrogen,    halogen,    C₁-C₆ alkyl,    C₃-C₆ alkenyl,    C₃-C₆ alkynyl,    R²⁰(CH₂)n- wherein R²⁰ represents C₃-C₈ cycloalkyl, naphthyl, phenyl, or phenyl substituted with one to five of C₁-C₄ alkyl, halogen atom, trifluoromethyl, hydroxy, C₁-C₄ alkoxy, C₁-C₃ acyloxy, amino, N-mono-C₁-C₄ alkylamino, N-di-C₁-C₄ alkylamino, C₁-C₄ thioalkyl, C₁-C₃ alkylsulfonyl, nitro, and -NHCOR²¹ wherein R²¹ represents C₁-C₃ alkyl, phenyl, C₁-C₃ alkylphenyl, aminophenyl, or C₁-C₄ alkylaminophenyl, and n is an integer of 1 to 6,    R²⁰-C(O)- wherein R²⁰ is as defined above, or    R²⁰-CH(OH)- wherein R²⁰ is as defined above; R² represents carbamoyl, mono- or di-C₁-C₆ alkylcarbamoyl, or 4- to 6-membered heterocyclic carbamoyl; R represents amino, carboxy, (1H-tetrazol-5-yl)phenyl, carboxyphenyl, carboxybenzamido, (1H-tetrazol-5-yl)benzamido, carboxyphenylcarbamoyl, or (1H-tetrazol-5-yl)-phenylcarbamoyl; R³ represents -CH₂(phenyl), -CH(phenyl)₂, -CH(phenyl)CH₃, -CH(phenyl) (cyclohexyl), -CH₂CH₂(phenyl), -CH₂(C₁-C₆ alkoxyphenyl), or -CH₂(hydroxyphenyl); and R⁴, R⁷, and R⁸ each independently represents hydrogen or C₁-C₆ alkyl, is an angiotensin II antagonist.

  式 (I) 的化合物： 或其药学上可接受的盐；其中 R¹ 代表 氢 卤素 C₁-C₆ 烷基 C₃-C₆ 烯基、 C₃-C₆ 烷基、 R²⁰(CH₂)n- 其中 R²⁰ 代表 C₃-C₈ 环烷基、萘基、苯基或被 1 至 5 个 C₁-C₄ 烷基取代的苯基、卤素原子、三氟甲基、羟基、C₁-C₄ 烷氧基、C₁-C₃酰氧基、氨基、N-单-C₁-C₄ 烷基氨基、N-二-C₁-C₄烷基氨基、C₁-C₄硫烷基、C₁-C₃烷基磺酰基、硝基和-NHCOR²¹，其中 R²¹ 代表 C₁-C₃烷基、苯基、C₁-C₃ 烷基苯基、氨基苯基或 C₁-C₄ 烷氨基苯基，且 n 为 1-6 的整数、 R²⁰-C(O)- 其中 R²⁰ 如上定义，或 R²⁰-CH(OH)- 其中 R²⁰ 如上定义； R² 代表氨基甲酰基、单-或双-C₁-C₆ 烷基氨基甲酰基或 4-6 元杂环氨基甲酰基； R 代表氨基、羧基、(1H-四唑-5-基)苯基、羧基苯基、羧基苯甲酰胺基、(1H-四唑-5-基)苯甲酰胺基、羧基苯基氨基甲酰基或 (1H-四唑-5-基)-苯基氨基甲酰基； R³ 代表-CH₂(苯基)、-CH(苯基)₂、-CH(苯基)CH₃、-CH(苯基)(环己基)、-CH₂CH₂(苯基)、-CH₂(C₁-C₆烷氧基苯基)或-CH₂(羟基苯基)；以及 R⁴、R⁷ 和 R⁸ 各自独立地代表氢或 C₁-C₆ 烷基，是血管紧张素 II 拮抗剂。
• Stabilized minimal coiled-coil mimetics
  申请人：NEW YORK UNIVERSITY

  公开号：US10851133B2

  公开（公告）日：2020-12-01

  This invention relates to a macrostructure that includes an antiparallel coiled-coil structure shown below or a parallel coiled-coil structure shown below and described in the present application.

  本发明涉及一种宏观结构，它包括下图所示的反平行盘卷结构或下图所示的平行盘卷结构，并在本申请中进行了描述。
• 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF
  申请人：Gorden Anne E. V.

  公开号：US20120028362A1

  公开（公告）日：2012-02-02

  Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.